AtriCure (ATRC) Cost of Revenue (2010 - 2026)

AtriCure (ATRC) has 17 years of Cost of Revenue data on file, last reported at $31.9 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 3.05% year-over-year to $31.9 million in Q1 2026; TTM through Mar 2026 was $134.7 million, a 11.14% increase from a year earlier, with the FY2025 full-year figure at $133.7 million, up 13.56% from the prior year.
• Cost of Revenue for Q1 2026 stood at $31.9 million, down from $35.2 million in the prior quarter.
• Over the last five years, Cost of Revenue for ATRC reached as high as $35.2 million in Q4 2025 and fell as low as $19.0 million in Q1 2022.
• Historically, Cost of Revenue has averaged $27.5 million across 5 years, with a median of $27.6 million in 2024.
• Across the five-year window, Cost of Revenue climbed 28.82% in 2022 and rose 3.05% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $22.9 million in 2022, then advanced by 16.64% to $26.7 million in 2023, then climbed by 18.45% to $31.7 million in 2024, then climbed by 11.07% to $35.2 million in 2025, then declined by 9.17% to $31.9 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $31.9 million in Q1 2026, $35.2 million in Q4 2025, and $32.9 million in Q3 2025.